Benefits
Heart Health
A meta-analysis of 20 randomized trials in 808 people found drops in systolic blood pressure (about 4.0 mmHg), diastolic pressure (1.4 mmHg) and heart rate (3.6 beats per minute), plus better heart pumping measures in people with heart failure, with no more adverse effects than control. In 120 adults with higher than ideal blood pressure, 1.6 g a day lowered clinic systolic pressure 7.2 mmHg versus 2.6 mmHg on placebo.
Exercise Performance
A meta-analysis of 10 studies using 1 to 6 grams a day found a small improvement in endurance performance (effect size 0.40) and in time to exhaustion (effect size 0.43). A single dose before exercise worked as well as daily use for up to 2 weeks, and larger doses did not work better.
Insulin and Blood Sugar Markers
In a placebo-controlled trial, 45 people with type 2 diabetes took 3,000 mg a day for 8 weeks; fasting blood sugar, insulin, insulin resistance (HOMA-IR), total and LDL cholesterol improved, but HbA1c, triglycerides, HDL and weight did not change. In a second trial of 120 people on a low-calorie diet, insulin and HOMA-IR fell, but fasting blood sugar and HbA1c did not.
Antioxidant and Anti-Inflammatory Blood Markers
In two 8-week trials in people with type 2 diabetes (50 and 120 people), MDA (a marker of oxidative damage), hs-CRP and TNF fell on taurine, and one also found higher activity of the antioxidant enzymes SOD and catalase than placebo. In 24 women aged 55 to 70, SOD rose on taurine. These small trials measured blood markers, not health outcomes.
Muscle Recovery After Hard Eccentric Exercise
Three small trials in men gave mixed results. In 21 young men, taurine started 14 days before hard elbow-flexor exercise led to better strength and less soreness and creatine kinase during recovery than placebo. In 10 men taking 0.1 g per kg a day for 3 days afterward, only peak eccentric torque improved, and 9 triathletes on 3 g a day saw no benefit.
Mechanism of action
Membrane Stabilization and Calcium Homeostasis
Taurine interacts with membrane phospholipids and helps regulate calcium channels and pumps, which matter for muscle contraction, nerve signalling and heart function. This is laboratory biology; the human trials measured blood pressure, heart rate, pumping function and exercise capacity, not these pathways.
Antioxidant Activity
In laboratory work taurine supports antioxidant enzymes such as superoxide dismutase and forms taurine chloramine with hypochlorous acid. Small human trials reported higher SOD and catalase activity and lower MDA, a marker of oxidative damage, but these are blood markers rather than proof of a health effect.
Osmoregulation
As an organic osmolyte, taurine regulates cell volume by balancing intracellular and extracellular osmotic pressure. This is particularly important in cells exposed to osmotic stress, such as in the kidneys, brain, and eyes, helping maintain cellular function under varying conditions.
Neurotransmitter Modulation
Taurine interacts with GABA and glycine receptors in the brain and increases inhibitory signalling in laboratory studies. None of the human trials cited here tested mood, anxiety, sleep or other brain outcomes.
Mitochondrial Function and Energy Metabolism
Taurine helps stabilize mitochondrial membranes and conjugates with bile acids, which aid fat digestion. Better mitochondrial efficiency in muscle is a proposed explanation for the small endurance effect in the exercise pooled analysis, but the human studies measured performance, not mitochondrial function.
Anti-inflammatory Effects
In laboratory studies taurine dampens pro-inflammatory signals such as TNF-alpha and IL-1 beta. Two trials in people with type 2 diabetes reported lower hs-CRP and TNF on taurine, but these are blood markers, not a demonstrated health benefit.
Insulin Sensitivity and Glucose Regulation
Taurine is proposed to improve insulin signalling by reducing oxidative stress and inflammation in insulin-sensitive tissues. Two 8-week trials in people with type 2 diabetes found lower insulin and insulin resistance (HOMA-IR) on taurine, but neither improved HbA1c.
Clinical trials
Multi-species study of blood taurine and aging, with taurine supplementation in worms, mice and monkeys and observational human blood data; no human supplementation was tested. (Singh et al. 2023, Science)
Multi-species: C. elegans, mice, monkeys, and human blood data including 11,966 adults in the EPIC-Norfolk study.
Blood taurine fell with age in mice, monkeys and humans in this study, although a 2025 US National Institute on Aging analysis (Fernandez et al., Science) found it rose or stayed flat with age in three human groups, monkeys and mice. In middle-aged mice of both sexes, taurine raised median lifespan by 10 to 12%, and in worms by 10 to 23%; it also improved healthspan measures in worms, mice and monkeys. In humans the data are observational (lower taurine was linked with several age-related diseases), and the authors called for clinical trials.
Systematic review and meta-analysis of 25 randomized trials (0.5 to 6 g/day for 5 to 365 days) measuring metabolic syndrome risk factors such as blood pressure, fasting glucose and blood fats. (Tzang et al. 2024, Nutr Diabetes)
1,024 participants pooled across 25 randomized trials.
Compared with control, taurine lowered systolic blood pressure by 4.0 mmHg, diastolic by 1.5 mmHg, fasting blood glucose by 5.9 mg/dL and triglycerides by 18.3 mg/dL, but did not change HDL cholesterol, with no significant adverse effects. Larger total doses were linked to bigger drops in diastolic pressure and fasting glucose. One pooled heart-failure trial (Ahmadian 2017, J Diet Suppl) was retracted in 2026.
Double-blind trial of 1.5 g taurine or a starch placebo for 16 weeks, with oxidative stress markers as primary outcomes. (Abud et al. 2022, Nutrition)
24 women aged 55 to 70 (13 taurine, 11 placebo); very small.
SOD, an antioxidant enzyme, rose on taurine and ended higher than in the placebo group; MDA, a marker of oxidative damage, rose only in the placebo group, and glutathione reductase fell in both groups. A very small trial whose main outcomes were blood markers, so it cannot show an anti-aging effect.
Double-blind, placebo-controlled trial of 1,000 mg taurine three times daily for 8 weeks, measuring oxidative stress and inflammation markers. Same team, dose and length as the 2020 blood sugar trial, so it may describe the same patients. (Maleki et al. 2020, Diabetol Metab Syndr)
50 people with type 2 diabetes (45 completed).
Compared with placebo, taurine lowered MDA (a marker of oxidative damage), hs-CRP and TNF-alpha and raised the antioxidant enzymes SOD and catalase; IL-6 and total antioxidant capacity did not differ. These are blood markers in a small group already under diabetes care, not evidence of a treatment effect.
Double-blind, placebo-controlled trial of 1.6 g taurine a day or placebo for 12 weeks, measuring blood pressure and vascular function. (Sun et al. 2016, Hypertension)
120 prehypertensive adults.
Clinic systolic blood pressure fell by an average 7.2 mmHg on taurine versus 2.6 mmHg on placebo (diastolic 4.7 versus 1.3 mmHg), and 24-hour ambulatory systolic pressure by 3.8 versus 0.3 mmHg. Blood vessel relaxation (vasodilation) also improved. The gap versus placebo, about 4.6 mmHg clinic systolic, is similar to the 4 mmHg average in the 20-trial meta-analysis.
Randomized trial of 1 g taurine or placebo three times daily for 8 weeks, with everyone on a low-calorie diet. (Moludi et al. 2022, Nutr Metab (Lond))
120 people with type 2 diabetes (60 per group).
Both groups followed a low-calorie diet, so the comparison with placebo isolates taurine. Insulin and insulin resistance (HOMA-IR) fell more on taurine than placebo, but fasting blood glucose, HbA1c and blood lipids did not improve. MDA, TNF and hs-CRP fell on taurine, and endothelial dysfunction markers were lower than on placebo.
Systematic review and meta-analysis of randomized trials searched up to January 2, 2024, examining heart rate, blood pressure, ejection fraction and heart failure class. (Tzang et al. 2024, Nutr J)
808 participants pooled across 20 randomized trials, many of them in people with diagnosed heart conditions.
Taurine lowered heart rate by 3.58 beats per minute, systolic blood pressure by 4.00 mmHg and diastolic by 1.44 mmHg, raised left ventricular ejection fraction by 4.98 percentage points and improved NYHA heart failure class by 0.40 points, with no significant adverse effects. Many of the pooled trials enrolled people with diagnosed heart conditions, 14 of the 20 did not report how treatment allocation was concealed, and one pooled heart-failure trial (Ahmadian 2017, J Diet Suppl) was retracted in 2026.